ArticleOncology letters2026
Integrated bioinformatics and feature selection-based discovery of ADP-ribosylation-associated biomarkers in non-small cell lung cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains a significant global health concern. ADP-ribosylation, a key post-translational modification, may influence the tumor immune microenvironment; however, the genes transcriptionally linked to ADP-ribosylation pathway activity in NSCLC are poorly understood. In the present study, transcriptomic data from the Gene Expression Omnibus database were analyzed to identify differentially expressed genes (DEGs) associated with ADP-ribosylation via differential expression analysis. Weighted gene co-expression network analysis was subsequently applied to refine these DEGs and extract ADP-ribosylation-related module genes. Feature selection methods aided by machine learning, including LASSO regression and the Boruta algorithm, were employed to identify core signature genes. Enzyme-linked immunosorbent assay (ELISA) validated poly(ADP-ribose) polymerase (PARP) protein levels in NSCLC tissues. Immune infiltration analysis, single-gene gene-set enrichment analysis and regulatory network construction were used to explore gene functions. ELISA confirmed significantly higher PARP concentrations in NSCLC tissues compared to para-cancerous tissues (P<0.01), indicating dysregulated ADP-ribosylation pathway activity. Three signature genes (HBZ, HLA-DRA and CCL4) were identified, all of which were significantly associated with immune-cell infiltration and immune factor expression. Reverse transcription-quantitative PCR validation in 10 paired NSCLC patient samples revealed a significant downregulation of HBZ (P<0.0001) and CCL4 (P<0.01), while HLA-DRA showed a non-significant downward trend. This study provides preliminary evidence that HBZ, HLA-DRA and CCL4 are transcriptionally linked to ADP-ribosylation pathway activity and may modulate the NSCLC immune microenvironment, offering potential avenues for future immunotherapeutic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.